Repligen Corp. diskutieren
Repligen Corp.
WKN: 870980 / Symbol: RGEN / Name: Repligen Corp / Aktie / Pharmazeutika / Mid Cap /
112,00 €
-0,70 %
Repligen Co. (NASDAQ: RGEN) is now covered by analysts at TD Cowen. They set a "buy" rating and a $200.00 price target on the stock.
Ratings data for RGEN provided by MarketBeat
Repligen Co. (NASDAQ: RGEN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $180.00 price target on the stock.
Ratings data for RGEN provided by MarketBeat
Repligen Co. (NASDAQ: RGEN) had its price target raised by analysts at JPMorgan Chase & Co. from $190.00 to $200.00. They now have an "overweight" rating on the stock.
Ratings data for RGEN provided by MarketBeat
Repligen Co. (NASDAQ: RGEN) had its price target raised by analysts at Royal Bank of Canada from $203.00 to $205.00. They now have an "outperform" rating on the stock.
Ratings data for RGEN provided by MarketBeat
Repligen Co. (NASDAQ: RGEN) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Ratings data for RGEN provided by MarketBeat
Repligen Co. (NASDAQ: RGEN) was upgraded by analysts at Wolfe Research from a "peer perform" rating to an "outperform" rating. They now have a $160.00 price target on the stock.
Ratings data for RGEN provided by MarketBeat
Repligen Co. (NASDAQ: RGEN) had its price target lowered by analysts at Royal Bank of Canada from $202.00 to $189.00. They now have an "outperform" rating on the stock.
Ratings data for RGEN provided by MarketBeat
Repligen Co. (NASDAQ: RGEN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $180.00 price target on the stock.
Ratings data for RGEN provided by MarketBeat
Repligen Corporation (NASDAQ: RGEN) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating.
Ratings data for RGEN provided by MarketBeat
Repligen Corporation (NASDAQ: RGEN) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $150.00 price target on the stock.
Ratings data for RGEN provided by MarketBeat
Repligen Corporation (NASDAQ: RGEN) is now covered by analysts at Stephens. They set an "overweight" rating and a $160.00 price target on the stock.
Ratings data for RGEN provided by MarketBeat
Repligen Corporation (NASDAQ: RGEN) had its price target lowered by analysts at Wells Fargo & Company from $180.00 to $175.00. They now have an "overweight" rating on the stock.
Ratings data for RGEN provided by MarketBeat
Repligen Corporation (NASDAQ: RGEN) had its price target raised by analysts at Royal Bank Of Canada from $193.00 to $204.00. They now have an "outperform" rating on the stock.
Ratings data for RGEN provided by MarketBeat
Repligen (NASDAQ:RGEN) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $180.00 price target on the stock.
Ratings data for RGEN provided by MarketBeat
Repligen (NASDAQ:RGEN) was upgraded by analysts at Evercore ISI from an "in-line" rating to an "outperform" rating. They now have a $155.00 price target on the stock, up previously from $130.00.
Ratings data for RGEN provided by MarketBeat
Repligen (NASDAQ:RGEN) was given a new $150.00 price target on by analysts at HSBC Holdings plc. They now have a "buy" rating on the stock.
Ratings data for RGEN provided by MarketBeat
Repligen (NASDAQ:RGEN) had its "overweight" rating reaffirmed by analysts at Barclays PLC.
Ratings data for RGEN provided by MarketBeat
Repligen (NASDAQ:RGEN) had its price target raised by analysts at Evercore ISI from $155.00 to $175.00. They now have an "outperform" rating on the stock.
Ratings data for RGEN provided by MarketBeat
Repligen (NASDAQ:RGEN) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Ratings data for RGEN provided by MarketBeat
Repligen (RGEN) had its "overweight" rating reaffirmed by KeyCorp.
Ratings data for RGEN provided by MarketBeat
Neueste Beiträge
Barrington_Research in Merit Medical Systems diskutieren